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INTRODUCTION
The purpose of this study is to functionally identify novel breast tumor suppressor genes. We have used an RNA interference (RNAi) based, forward genetic approach to identify genes that suppress oncogenic transformation of normal human breast epithelial cells in vivo. The identification of these genes will improve the understanding of the causes of breast cancer, which may lead to therapeutic advancements for breast cancer prevention and treatment.
BODY
Objective 1: Identification of breast tumor suppressors using in vitro and in vivo RNAi screens (Months 1-14) Original plan: Partially transformed human mammary epithelial cells (HMLEs) and primary breast epithelial cells (BPLEs) will be used for an RNAi screen to identify breast tumor suppressors. HMLEs and BPLEs will be infected with the Expression Arrest GIPZ lentiviral shRNAmir library consisting of 70,000 shRNAmirs targeting the whole human genome. shRNAmirs that silence tumor suppressors will fully transform HMLEs and BPLEs. Fully transformed cells will be identified by their ability to proliferate in the absence of extracellular matrix and form tumors in immunodeficient mice. Sequencing will identify the integrated shRNAmirs capable of full transformation. Target genes silenced by the identified shRNAmirs are candidate breast tumor suppressor genes capable of suppressing breast epithelial cell transformation.
Task 1A: Obtain regulatory approval (Months 1-3): COMPLETE Regulatory approval from the Institutional Biosafety Committee (IBC) and Institutional Animal Care and Use Committee (IACUC) has been obtained for the proposed experiments (Appendices A and B).

Task 1B: Prepare GIPZ shRNAmir library (Months 4-5): COMPLETE
Seven pools containing 10,000 GIPZ shRNAmir constructs were replicated in PrimePlus competent E.coli. Plasmid DNA was extracted using the Qiagen HiSpeed Maxi Kit. Plasmid DNA was digested with SacII restriction enzyme and visualized on an agarose gel with uncut DNA for diagnostic quality control (Supporting data, Figure 1 ). Plasmid pools showed no indication of recombination and passed quality control. Each pool of GIPZ shRNAmir plasmid DNA was packaged into lentiviral particles for transduction. Supernatants containing GIPZ shRNAmir lentivirus were harvested for transduction of partially transformed breast epithelial cells.
Task 1C: Complete in vitro shRNAmir screens (Months 6-8): ATTEMPTED, NOT COMPLETED DUE TO TECHNICAL ISSUES
BPLE cells proved very difficult to culture, resulting in an inability to generate enough BPLE cells for either the in vitro or in vivo RNAi screens. Therefore work was continued with only the HMLE cells.
The read-out for the in vitro RNAi screens is anchorage independent growth detected by the ability to form colonies in soft agar. Our screen depended on the HMLE cells gaining the ability to form colonies in soft agar by shRNA silencing of a tumor suppressor gene. Unfortunately our control experiments demonstrated that HMLE cells transduced with GIPZ non-silencing control already have some capability to form colonies in soft agar (Supporting data, Figure 2 ). Therefore they are not suitable for conducting an in vitro RNAi screen as the rate of false positives caused by spontaneous colony growth would be unacceptably high.
We are currently conducting experiments to determine whether primary mammary epithelial cells cultured from murine mammary glands are suitable for performing an in vitro RNAi screen. Primary murine mammary epithelial cells will be harvested and transduced with GIPZ nonsilencing control or oncogenic Ras and their ability to form colonies in soft agar will be assessed. We expect that GIPZ non-silencing control cells will fail to form colonies and oncogenic Ras transduced cells will gain the ability to form colonies. If this is the case, these cells will be used for an in vitro RNAi screen to identify tumor suppressor genes.
Task 1D: Complete in vivo shRNAmir screens (Months 9-12): COMPLETE BPLE cells proved very difficult to culture, resulting in an inability to generate enough BPLE cells for either the in vitro or in vivo RNAi screens. Therefore work was continued with only the HMLE cells.
Each pool of lentiviral packaged GIPZ shRNAmirs was used to infect six flasks of HMLE cells. In addition, per pool six flasks of HMLE cells were infected with lentiviral packaged GIPZ nonsilencing control. Cells were transduced at a multiplicity of infection of 0.3 to ensure each cell integrated a single shRNAmir. 1000 cells per shRNAmir construct were transduced based on optimization experiments that demonstrated 1000 transformed cells could generate tumors in severely immunocompromised NSG mice. Nontransduced cells were removed by puromycin selection. Following puromycin selection, stably transduced cells were xenografted into the fourth mammary fat pads of NSG mice. To control for the rate of spontaneous transformation and viral insertional mutagenesis, mice were injected on the contralateral side with an equal number of HMLE cells infected with GIPZ non-silencing control. Six mice were injected per pool Table 1 ). Specifically, virally integrated gene-specific shRNAmir sequences were PCR amplified from genomic DNA using primers that also contain the sequences required for cluster generation using the Illumina Genome Analyser II (GAII) platform. After cluster generation, clusters were sequenced on the GAII, using a primer that is complementary to a sequence flanking the gene-specific region of each shRNAmir. The output from the GAII comprises the identity and frequency of short DNA sequences representing the gene-specific target sequences of each shRNAmir. Identified shRNAs silence candidate breast tumor genes capable of suppressing breast epithelial cell transformation.
To support the results from NGS, we TOPO cloned and Sanger sequenced shRNA PCR products from all 19 tumors (Supporting data, Table 2 ). These approaches yielded a number of similar results. Importantly, previously characterized tumor suppressor genes including TP53 (1, 2) and MNT (3, 4) were identified, validating our in vivo RNAi screening strategy. In addition, many other candidate tumor suppressors were identified.
Our in vivo screen identified two individual shRNAs (V2LHS_7397 and V2LHS_133982) targeting the Leukemia Inhibitory Factor Receptor gene (LIFR) (Supporting data, Table 1 ) in tumors derived from multiple mice, reducing the likelihood that LIFR represented a false positive hit (5). In addition, we confirmed that the presence of LIFR shRNA in the tumors was not due to unusually high representation in the pre-xenografted HMLE cells (Supporting data, Figure 5 ), indicating that the identification of LIFR was unlikely to be an artifact. Analysis of screen hit gene lists with the STRING protein interaction database (string-db.org) highlighted the interaction between LIFR and Ciliary Neurotrophic Factor Receptor (CNTFR) (6), an additional in vivo screen hit (Supporting data, Figure 6 ). Analysis of multiple genome-wide RNAi screens in Drosophila melanogaster has demonstrated that the identification of multiple components within protein-protein interaction networks is indicative of true positive hits (7). Therefore the identification of CNTFR further emphasizes the likelihood that LIFR is a positive hit from the in vivo RNAi screen.
LIFR is a subunit of the heterodimeric receptor for leukemia inhibitory factor (LIF). LIFR is expressed in normal breast epithelium, suggesting that LIFR function may be important in the normal breast. Although important in normal breast physiology, a potential role for LIFR as a breast tumor suppressor has not been previously described. Evidence that the LIF pathway may be mammary tumor suppressive is provided by mouse models of LIF deletion, which have defects in mammary epithelial apoptosis during post-lactational involution (8).
LIFR is one of the most promising candidates from our in vivo RNAi screen. Our future work will determine whether LIFR and other candidates are clinically significant novel breast tumor suppressor genes.
KEY RESEARCH ACCOMPLISHMENTS
• Obtained regulatory approval for study shRNA ID Pool Target 1  Target 2  Targets Median  sequence reads   % tumors  present   shRNAs/  gene  V2LHS_133982 3  LIFR  1  164141  100  2  V2LHS_7397  1  LIFR  1  120077  100  2  V2LHS_132866 5  ATP6V1C1  1  57265  33  2  V2LHS_132867 4  ATP6V1C1  1  31071  100  2  V2LHS_93615  5  TP53  FXR2  2  499650  33  2  V2LHS_217  1  TP53  FXR2  2  3375 1  900149  100  1  V2LHS_175007 2  RNF121  1  883033  40  1  V2LHS_51176  5  FBXL7  1  841655  100  1  V2LHS_117561 2  L3MBTL2  1  827013  40  1  V2LHS_173142 1  GUCY1B2  1  688827  33  1  V2LHS_218555 1  ZBTB17  1  638940  33  1  V2LHS_46777  3  TAAR5  1  634677  100  1  V2LHS_47611  5  MAP4K2  1  623917  83  1  V2LHS_112635 7  BUB1B  1  618581  50  1  V2LHS_266098 1  AC010634.1  1  618470  33  1  V2LHS_152280 1  GPNMB  1  489561  33  1  V2LHS_213752 1  ASCC3  1  488422  33  1  V2LHS_131392 1  POLR2B  1  467182  33  1  V2LHS_257730 1  MCOLN2  SYDE2  2  464493  33  1  V2LHS_98652  1  MRP63  ZMYM2  2  459575  33  1  V2LHS_68041  3  DIS3L2  EIF4E2  2  452545  100  1  V2LHS_174587 2  PID1  1  411779  60  1  V2LHS_150703 1  CNTFR  1  387166  33  1  V2LHS_171793 1  UBE2N  1  353683  33  1  V2LHS_169903 5  PFKP  1  347281  33  1  V2LHS_58990  1  B3GALTL  N4BP2L1  2  343719  33  1  V2LHS_8705  1  WHSC1  1  317411  33  1  V2LHS_66509  3  DMTF1  1  316145  75  1  V2LHS_155301 5  FRMD4A  1  307011  33  1  V2LHS_155295 5  PACS1  1  292135  33  1  V2LHS_60727  5  USP22  1  269208  33  1  V2LHS_131441 1  PRIM2  1  263467  50  1  V2LHS_168960 1  CDA  1  230849  33  1  V2LHS_96376  6  WDFY3  1  217892  100  1  V2LHS_117997 1  PRAM1  1  208361  33  1  V2LHS_182675 5  KIAA1602  SENP1  2  204929  33  1  V2LHS_82602  6  HADHB  RAB10  2  192323  100  1  V2LHS_87361  4  MLST8  1 V2LHS_24996  5  2  CA14  1  14  V2LHS_50258  5  2  XR_016873  4  57  V2LHS_142260 5  2  XR_017265  1  14  V2LHS_51176  5  3  FBXL7  8  44  V2LHS_47611  5  3  MAP4K2  2  11  V2LHS_246460 5  3  ZDHHC15  2  11  V2LHS_256533 5  3  PEX12  1  6  V2LHS_191885 5  3  FKBP1A  1  6  V2LHS_179595 5  3  ITGA1  1  6  V2LHS_183847 5  3  Z98036  1  6  V2LHS_182675 5  3  Unknown  1  6  V2LHS_34838  5  3  Unknown  1  6  V2LHS_73744  6  1  RNY4  1  10  V2LHS_30715  6  1  AC025035  1  10  V2LHS_120707 6  1  OR5J7P  1  10  V2LHS_114931 6  1  PRLH  1  10  V2LHS_259788 6  1  AL590095  1  10  V2LHS_205654 6  1  AC021150  4  40  V2LHS_131528 6  1  PTGS1  1  10  V2LHS_219840 7  1  CBR4  3  27  V2LHS_123243 7  1  KRT27  3  27  V2LHS_96369  7  1  RIMS1  1  9  V2LHS_90902  7  1  PIF1  1  9  V2LHS_149971 7  1  CRPP1  1  9  V2LHS_23683  7  1  AC126469  1  9  V2LHS_78374  7  1  AC083949  1  9  V2LHS_118826 7  2  CMTM8  1  10  V2LHS_265739 7  2  FGFR1OP2  1  10  V2LHS_165312 7  2  AMTN  1  10  V2LHS_219613 7  2  AL358937  1  10  V2LHS_146428 7  2  AC120305  1  10  V2LHS_285756 7  2  BTN2A1  1  10  V2LHS_36022  7  2  STK17A  2  20  V2LHS_20834  7  2  ITGA11  1  10  V2LHS_135243 7  2  TLR8  1  10 
